What is Depixus?
Depixus is at the forefront of molecular diagnostics, specializing in a suite of technologies designed to revolutionize the way genetic and epigenetic data is extracted. Their innovative approach targets single molecules of DNA and RNA, promising unprecedented speed, accuracy, and affordability in genetic analysis. With commercial development actively underway, Depixus is poised to make a substantial impact on fields ranging from personalized medicine to fundamental biological research.
How much funding has Depixus raised?
Depixus has raised a total of $35.4M across 1 funding round:
Series A
$35.4M
Series A (2021): $35.4M with participation from Casdin Capital, Arix Bioscience, Lansdowne Partners, and Bpifrance
Key Investors in Depixus
Arix Bioscience
Arix Bioscience is a global venture capital firm dedicated to investing in and building breakthrough biotech companies, leveraging cutting-edge advances in life sciences to accelerate new treatments for patients.
Lansdowne Partners
Lansdowne Partners is an investment management partnership established in 1998, focused on delivering superior long-term investment returns and exceptional client service.
Bpifrance
Bpifrance is a French public investment bank that finances companies at every stage of development, supporting them with credit, guarantees, equity, and international expansion.
What's next for Depixus?
The substantial enterprise-level funding, particularly the recent Series A financing, positions Depixus for accelerated commercialization and market penetration. This capital infusion will likely fuel the scaling of manufacturing, expansion of sales and marketing efforts, and further research and development to broaden the application of their proprietary extraction technologies. Strategic partnerships and broader adoption within the life sciences sector are anticipated as the company moves from advanced validation to full-scale market engagement.
See full Depixus company page
